Artwork

Kandungan disediakan oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma

47:30
 
Kongsi
 

Manage episode 366328158 series 3369804
Kandungan disediakan oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:

1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9

2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:

a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/

b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/

3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:

a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/

b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/

3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma:
https://pubmed.ncbi.nlm.nih.gov/36690811/

4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma:
https://pubmed.ncbi.nlm.nih.gov/36413381/

  continue reading

54 episod

Artwork
iconKongsi
 
Manage episode 366328158 series 3369804
Kandungan disediakan oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:

1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9

2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:

a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/

b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/

3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:

a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/

b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/

3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma:
https://pubmed.ncbi.nlm.nih.gov/36690811/

4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma:
https://pubmed.ncbi.nlm.nih.gov/36413381/

  continue reading

54 episod

Усі епізоди

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas